Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• NX-5948

Snippet

Sponsor: Nurix Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Status: RECRUITING